Cartherics’ CEO, Professor Alan Trounson, was recently interviewed by CGTLive, to discuss the company’s development of NK cell, T-cell and macrophage cell therapies for various solid tumours.

Cartherics is using its induced pluripotent stem (iPS) cell platform to develop NK cell, T-cell, and macrophage cell therapies with potential indications for solid tumour types including ovarian, gastric, prostate, pancreatic, liver, and kidney cancers.

He also discusses several of the company’s near-term pipeline products and other areas of possible development for the future, including the potential for introducing a memory component to cell therapies to help protect against future occurrences of cancer. Watch the interview here.